BRPI0414266A - derivados de tiazolopiridina como ligandos receptores da adenosina - Google Patents
derivados de tiazolopiridina como ligandos receptores da adenosinaInfo
- Publication number
- BRPI0414266A BRPI0414266A BRPI0414266-7A BRPI0414266A BRPI0414266A BR PI0414266 A BRPI0414266 A BR PI0414266A BR PI0414266 A BRPI0414266 A BR PI0414266A BR PI0414266 A BRPI0414266 A BR PI0414266A
- Authority
- BR
- Brazil
- Prior art keywords
- lower alkyl
- disease
- heterocyclyl
- compounds
- substituents selected
- Prior art date
Links
- 102000009346 Adenosine receptors Human genes 0.000 title abstract 2
- 108050000203 Adenosine receptors Proteins 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical class C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000011117 substance-related disease Diseases 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010013663 drug dependence Diseases 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 230000004112 neuroprotection Effects 0.000 abstract 2
- -1 tetrahydropyran-4-yl Chemical group 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"DERIVADOS DE TIAZOLOPIRIDINA COMO LIGANDOS RECEPTORES DA ADENOSINA". A presente invenção diz respeito aos compostos da fórmula geral (I) em que R¬ 1¬ é morfolin-4-ila, fenila ou tetraidropiran-4-ila; R¬ 2¬ é -(CH~ 2~)~ n~-arila, não substituída ou substituída por um ou mais substituintes, selecionados do grupo consistindo de halogeno, alcóxi inferior, alquila inferior, -(CH~ 2~)~ n~NR<39>R<39><39>, -O(CH~ 2~)~ n~-O-alquila inferior, ou -(CH~ 2~)~ n~-heterociclila, ou é heteroarila, não substituída ou substituída por um ou mais substituintes, selecionados do grupo consistindo de alquila inferior, alcóxi inferior, -(CH~ 2~)~ n~ NR<39>R<39><39>, -(CH~ 2~)~ n~heterociclila, que é opcionalmente substituída por hidróxi ou alcóxi inferior, ou é -(CH~ 2~)~ n~-heterociclila, opcionalmente substituída por um ou mais substituintes selecionados do grupo consistindo de -(CH~ 2~)~ n~-OH, -(CH~ 2~)~ n~-O-alquila inferior ou alquila inferior, ou é -(CH~ 2~)~ n~-cicloalquila, ou é -(CH~ 2~)~ n~-O-alquila inferior, ou é NR<39>R<39><39>, ou é benzo¢1,3!dioxol, 2-metil-1-oxo-2,8-diaza-espiro ¢4,5!decano, 2-oxa-5-aza-biciclo¢2,2,1!heptano ou 1-oxa-8-aza-espiro ¢4,5! decano; R<39>,R<39><39> são independentemente um do outro alquila inferior, -(CH~ 2~)~ n~O-alquila inferior ou cicloalquila, opcionalmente substituída por hidróxi; n é 0, 1 ou 2; e aos sais de adição de ácido farmaceuticamente aceitáveis destes. Estes compostos podem ser utilizados no controle ou prevenção de enfermidades que se baseiam na modulação do sistema de adenosina, tal como doença de Alzheimer, doença de Parkinson, doença de Huntington, neuro-proteção, esquizofrenia, ansiedade, dor, déficit da respiração, depressão, vício de drogas, tais como anfetamina, cocaína, opióides, etanol, nicotina, canabinóides, ou contra asma, respostas alérgicas, hipoxia, isquemia, ataque apoplético e abuso de substâncias. Além disso, os compostos da presente invenção podem ser úteis como sedativos, relaxantes musculares, antipsicóticos, antiepilépticos, anticonvulsivantes e agentes cardioprotetores para os distúrbios tais como doença da artéria coronária e insuficiência cardíaca. As indicações mais preferíveis de acordo com a presente invenção são aquelas que incluem os distúrbios do sistema nervoso central, por exemplo, o tratamento ou prevenção da doença de Alzheimer, certos distúrbios depressivos, vício de drogas, neuroproteção e doença de Parkinson assim como ADHD.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03021119 | 2003-09-19 | ||
| PCT/EP2004/010179 WO2005028484A1 (en) | 2003-09-19 | 2004-09-11 | Thiazolopyridine derivatives as adenosine receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414266A true BRPI0414266A (pt) | 2006-11-07 |
Family
ID=34306777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414266-7A BRPI0414266A (pt) | 2003-09-19 | 2004-09-11 | derivados de tiazolopiridina como ligandos receptores da adenosina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7273865B2 (pt) |
| EP (1) | EP1670805A1 (pt) |
| JP (1) | JP2007505851A (pt) |
| KR (1) | KR20060058132A (pt) |
| CN (1) | CN1871244A (pt) |
| AR (1) | AR045659A1 (pt) |
| AU (1) | AU2004274154A1 (pt) |
| BR (1) | BRPI0414266A (pt) |
| CA (1) | CA2539314A1 (pt) |
| MX (1) | MXPA06002943A (pt) |
| RU (1) | RU2006112847A (pt) |
| TW (1) | TWI297339B (pt) |
| WO (1) | WO2005028484A1 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| DK1803443T3 (en) | 2002-12-20 | 2019-02-25 | Niconovum Ab | Nicotine-containing particulate material with a crystalline cellulose |
| JP2008535790A (ja) * | 2005-03-03 | 2008-09-04 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体 |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1909910A1 (en) * | 2005-08-04 | 2008-04-16 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US20070213311A1 (en) * | 2006-03-02 | 2007-09-13 | Yun-Long Li | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| CA2646942C (en) | 2006-03-16 | 2014-07-29 | Modoral Brands Inc. | Improved snuff composition |
| US20070293529A1 (en) * | 2006-05-01 | 2007-12-20 | Yun-Long Li | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 |
| WO2007134958A1 (en) * | 2006-05-18 | 2007-11-29 | F. Hoffmann-La Roche Ag | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists |
| FR2913886B1 (fr) | 2007-03-22 | 2012-03-02 | Guerbet Sa | Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| CA2704336A1 (en) * | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| JP2011503066A (ja) * | 2007-11-08 | 2011-01-27 | サートリス ファーマシューティカルズ， インコーポレイテッド | 可溶化チアゾロピリジン誘導体 |
| EA021424B1 (ru) | 2008-12-19 | 2015-06-30 | Сертрис Фармасьютикалз, Инк. | Тиазолопиридиновые соединения, регулирующие сиртуин |
| AU2014347027A1 (en) | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | GSK -3 inhibitors |
| KR102292433B1 (ko) * | 2013-11-06 | 2021-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Gsk-3 억제제로서 유용한 치환된 피리딘 유도체 |
| WO2015091584A1 (en) * | 2013-12-18 | 2015-06-25 | F. Hoffmann-La Roche Ag | Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors |
| CN103720703A (zh) * | 2013-12-24 | 2014-04-16 | 新乡医学院第一附属医院 | 腺苷a2a受体特异性阻断剂对延髓呼吸中枢的作用 |
| IT201600070952A1 (it) * | 2016-07-07 | 2018-01-07 | Univ Degli Studi Di Ferrara | NUOVI TIAZOLO[5,4-d]PIRIMIDIN DERIVATI QUALI AGONISTI INVERSI DEI RECETTORI A2A DELL’ADENOSINA |
| SG11202000823WA (en) | 2017-08-01 | 2020-02-27 | Merck Patent Gmbh | Thiazolopyridine derivatives as adenosine receptor antagonists |
| JP7287951B2 (ja) | 2017-08-21 | 2023-06-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしてのキノキサリン誘導体 |
| CN110997662B (zh) | 2017-08-21 | 2023-10-31 | 默克专利股份公司 | 作为腺苷受体拮抗剂的苯并咪唑衍生物 |
| JP7551607B2 (ja) | 2018-10-25 | 2024-09-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体 |
| BR112021007435A2 (pt) | 2018-10-25 | 2021-08-03 | Merck Patent Gmbh | derivados de 5-azaindazol como antagonistas de receptor de adenosina |
| WO2020103930A1 (zh) * | 2018-11-22 | 2020-05-28 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
| AR117844A1 (es) * | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ522928A (en) * | 2000-06-21 | 2005-05-27 | F | Benzothiazole derivatives |
| US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| US6624163B2 (en) * | 2001-11-29 | 2003-09-23 | Hoffman-La Roche Inc. | Benzothiazole derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| KR100581703B1 (ko) * | 2001-12-12 | 2006-05-22 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 조절제로서의 벤조티오펜 |
| US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
| US6734179B2 (en) * | 2001-12-12 | 2004-05-11 | Hoffmann-La Roche Inc. | Benzothiazoles |
-
2004
- 2004-09-11 AU AU2004274154A patent/AU2004274154A1/en not_active Abandoned
- 2004-09-11 CA CA002539314A patent/CA2539314A1/en not_active Abandoned
- 2004-09-11 RU RU2006112847/04A patent/RU2006112847A/ru not_active Application Discontinuation
- 2004-09-11 WO PCT/EP2004/010179 patent/WO2005028484A1/en not_active Ceased
- 2004-09-11 EP EP04765102A patent/EP1670805A1/en not_active Ceased
- 2004-09-11 CN CNA2004800309594A patent/CN1871244A/zh active Pending
- 2004-09-11 KR KR1020067005454A patent/KR20060058132A/ko not_active Ceased
- 2004-09-11 MX MXPA06002943A patent/MXPA06002943A/es not_active Application Discontinuation
- 2004-09-11 BR BRPI0414266-7A patent/BRPI0414266A/pt not_active IP Right Cessation
- 2004-09-11 JP JP2006526568A patent/JP2007505851A/ja active Pending
- 2004-09-15 US US10/941,708 patent/US7273865B2/en not_active Expired - Fee Related
- 2004-09-16 AR ARP040103313A patent/AR045659A1/es not_active Application Discontinuation
- 2004-09-16 TW TW093128066A patent/TWI297339B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1670805A1 (en) | 2006-06-21 |
| US20050065151A1 (en) | 2005-03-24 |
| TWI297339B (en) | 2008-06-01 |
| WO2005028484A1 (en) | 2005-03-31 |
| AU2004274154A1 (en) | 2005-03-31 |
| US7273865B2 (en) | 2007-09-25 |
| AR045659A1 (es) | 2005-11-02 |
| KR20060058132A (ko) | 2006-05-29 |
| TW200526670A (en) | 2005-08-16 |
| CA2539314A1 (en) | 2005-03-31 |
| CN1871244A (zh) | 2006-11-29 |
| JP2007505851A (ja) | 2007-03-15 |
| RU2006112847A (ru) | 2007-11-10 |
| MXPA06002943A (es) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045659A1 (es) | Derivados de tiazolopiridina | |
| BRPI0415746A (pt) | derivados de amida | |
| BRPI0418082A (pt) | antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a | |
| AR039367A1 (es) | Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos | |
| BRPI0418102A (pt) | derivados de quinolina | |
| BRPI0409110A (pt) | derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer | |
| BR0214221A (pt) | Derivados de benzotiazol como ligantes de receptores de adenosina | |
| BR9707636A (pt) | Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo | |
| BRPI0512535A (pt) | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações | |
| BR0209271A (pt) | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto | |
| BRPI0415972A (pt) | derivados de diamina, processo para produção desses derivados, e agentes para controle de doenças de plantas os quais contêm esses derivados como ingredientes ativos | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BRPI0516219A (pt) | composto de carboestirila | |
| NO20081435L (no) | N-oksider som prodroger for piperazin- og piperidinderivater | |
| ES2028802T3 (es) | Procedimiento para preparar compuestos fenil(o heterociclo) tetrahidropiridil(o piperazinil)alcoxi-benzoheterociclicos utiles como antipsicoticos. | |
| UA86617C2 (en) | 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR | |
| BR0311840A (pt) | Composto, formulação farmacêutica, método para tratar ou evitar resistência à insulina, uso de um composto, e, processo para prepará-lo | |
| UA87142C2 (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide | |
| WO2008009741A1 (en) | Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same | |
| BRPI0518533A2 (pt) | 18-metil-19-nor-pregn-4-en-21,17- carbolactona, bem como preparados farmacÊuticos contendo as mesmas | |
| BRPI0408248A (pt) | derivados azabicìclicos de piridiloximetila e de benzisoxazol | |
| WO2008077810A3 (en) | Spiro-piperidine derivatives | |
| BR0213417A (pt) | Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos | |
| BRPI0517740A (pt) | compostos n-sulfonilaminobenzil-2fenóxi acetamida substituìda | |
| BRPI0409302A (pt) | derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |